Secure Drug Supply Chain Act of 2026
A bill to direct the Food and Drug Administration to prevent the importation of counterfeit, unapproved, misbranded, or adulterated drugs from the People's Republic of China or other foreign countries, to establish enhanced safeguards for imported drug products, and for other purposes.
This bill, SB5043, aims to strengthen the Food and Drug Administration's (FDA) ability to stop counterfeit, unapproved, misbranded, or adulterated drugs from entering the U.S. from China and other countries. It would also create stronger protections for drugs that are imported into the United States. The bill is designed to protect public health by ensuring that medications sold in the U.S. are safe and effective.
If passed, this bill would affect anyone who buys or uses prescription drugs. By improving the FDA's oversight of imported drugs, it aims to reduce the risk of harmful or ineffective medications reaching consumers. This includes both individuals and healthcare providers who rely on these drugs for treatment.
As of July 21, 2026, SB5043 has been introduced and referred to the Senate Committee on Health, Education, Labor, and Pensions. No further actions have been taken yet, but the committee will review the bill and may schedule hearings or votes. If approved by the committee, it will move forward in the legislative process for potential passage.
